AnaCardio
SwedenEntry
2022
Hold
4yr
Status
Active
Who owns AnaCardio?
AnaCardio is a Swedish Biotech company, currently owned by Novo Holdings since 2025 and 3 other investors.
Hand-verified · updated 2026-08-17
Open JSON · CC-BYMost recent investor
FlerieFlerie Invest · 2011 · Life Sciences VC
4 ownership periods · full history below
Key facts
HQSweden
SectorBiotech
StatusActive
Key takeaways
- ·Co-held by Karolinska Development, Industrifonden, Flerie and Novo Holdings since 2021.
- ·4 distinct PE sponsors across ownership cycles.
Ownership history
4 ownership periods · co-invest detected
Active
Co-invest · 4 holders · 2021 · present
Karolinska DevelopmentActive
2021 · present(5yr) · Karolinska Development · 2003 · Life Sciences VC
FlerieActive
2022 · present(4yr) · Flerie Invest · 2011 · Life Sciences VC
IndustrifondenActive
2022 · present(4yr) · Industrifonden Evergreen · 1991 · VC
Novo HoldingsActive
2025 · present(1yr) · Novo Holdings Venture Investments · 1999 · VC
More from Flerie Invest
Other portfolio companies in the same fund.
Germany
USMore PE-backed in Biotech
Comparable biotech deals from other GPs.
Questions
Who owns AnaCardio?
AnaCardio is currently owned by Novo Holdings, Industrifonden and 2 others, through Flerie Invest, since 2025.
When did Novo Holdings and 3 others acquire AnaCardio?
Novo Holdings and 3 others acquired AnaCardio in 2025.
Who has owned AnaCardio over time?
AnaCardio has been through 4 private-equity ownership periods: Karolinska Development · via Karolinska Development · since 2021; Industrifonden · via Industrifonden Evergreen · since 2022; Flerie · via Flerie Invest · since 2022; Novo Holdings · via Novo Holdings Venture Investments · since 2025.
Look up another firm or company
Data refreshed weekly · Sourced from public filings · Report an issue